Nature Communications (Nov 2021)
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
- Pietro Carotenuto,
- Francesco Amato,
- Andrea Lampis,
- Colin Rae,
- Somaieh Hedayat,
- Maria C. Previdi,
- Domenico Zito,
- Maya Raj,
- Vincenza Guzzardo,
- Francesco Sclafani,
- Andrea Lanese,
- Claudia Parisi,
- Caterina Vicentini,
- Ian Said-Huntingford,
- Jens C. Hahne,
- Albert Hallsworth,
- Vladimir Kirkin,
- Kate Young,
- Ruwaida Begum,
- Andrew Wotherspoon,
- Kyriakos Kouvelakis,
- Sergio Xavier Azevedo,
- Vasiliki Michalarea,
- Rosie Upstill-Goddard,
- Sheela Rao,
- David Watkins,
- Naureen Starling,
- Anguraj Sadanandam,
- David K. Chang,
- Andrew V. Biankin,
- Nigel B. Jamieson,
- Aldo Scarpa,
- David Cunningham,
- Ian Chau,
- Paul Workman,
- Matteo Fassan,
- Nicola Valeri,
- Chiara Braconi
Affiliations
- Pietro Carotenuto
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Francesco Amato
- Institute of Cancer Sciences, University of Glasgow
- Andrea Lampis
- Division of Molecular Pathology, The Institute of Cancer Research
- Colin Rae
- Institute of Cancer Sciences, University of Glasgow
- Somaieh Hedayat
- Division of Molecular Pathology, The Institute of Cancer Research
- Maria C. Previdi
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Domenico Zito
- Division of Molecular Pathology, The Institute of Cancer Research
- Maya Raj
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Vincenza Guzzardo
- Department of Medicine, University of Padua
- Francesco Sclafani
- The Royal Marsden NHS Trust, London and Surrey
- Andrea Lanese
- The Royal Marsden NHS Trust, London and Surrey
- Claudia Parisi
- The Royal Marsden NHS Trust, London and Surrey
- Caterina Vicentini
- ARC-Net Research Centre and Department of Diagnostics and Public Health, Section of Pathology, , University of Verona
- Ian Said-Huntingford
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Jens C. Hahne
- Division of Molecular Pathology, The Institute of Cancer Research
- Albert Hallsworth
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Vladimir Kirkin
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Kate Young
- The Royal Marsden NHS Trust, London and Surrey
- Ruwaida Begum
- The Royal Marsden NHS Trust, London and Surrey
- Andrew Wotherspoon
- The Royal Marsden NHS Trust, London and Surrey
- Kyriakos Kouvelakis
- The Royal Marsden NHS Trust, London and Surrey
- Sergio Xavier Azevedo
- The Royal Marsden NHS Trust, London and Surrey
- Vasiliki Michalarea
- The Royal Marsden NHS Trust, London and Surrey
- Rosie Upstill-Goddard
- Institute of Cancer Sciences, University of Glasgow
- Sheela Rao
- The Royal Marsden NHS Trust, London and Surrey
- David Watkins
- The Royal Marsden NHS Trust, London and Surrey
- Naureen Starling
- The Royal Marsden NHS Trust, London and Surrey
- Anguraj Sadanandam
- Division of Molecular Pathology, The Institute of Cancer Research
- David K. Chang
- Institute of Cancer Sciences, University of Glasgow
- Andrew V. Biankin
- Institute of Cancer Sciences, University of Glasgow
- Nigel B. Jamieson
- Institute of Cancer Sciences, University of Glasgow
- Aldo Scarpa
- ARC-Net Research Centre and Department of Diagnostics and Public Health, Section of Pathology, , University of Verona
- David Cunningham
- The Royal Marsden NHS Trust, London and Surrey
- Ian Chau
- The Royal Marsden NHS Trust, London and Surrey
- Paul Workman
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Matteo Fassan
- Department of Medicine, University of Padua
- Nicola Valeri
- Division of Molecular Pathology, The Institute of Cancer Research
- Chiara Braconi
- Division of Cancer Therapeutics, The Institute of Cancer Research
- DOI
- https://doi.org/10.1038/s41467-021-27099-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Understanding which patients will respond to FOLFIRINOX therapy is important for clinical outcome. Here, the authors show that the MIR1307 is increased pancreatic cancer cell lines and inhibition of the microRNA sensitises cells to treatment.’ stratifying patients to achieve the best clinical outcome. Here, the authors show that the MIR1307 is increased in a subgroup of human pancreatic cancers and inhibition of the microRNA in in vitro and in vivo models of pancreatic cancer sensitises cells to treatment.
